AXLA:NSD-Axcella Health Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 4.24

Change

-0.12 (-2.75)%

Market Cap

USD 0.16B

Volume

0.22M

Average Target Price

USD 16.00 (+277.36%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Axcella Health Inc. operates as a clinical stage biotechnology company in the United States. It treats complex diseases and enhances health using endogenous metabolic modulator compositions. The company's lead product candidates include AXA1665 for the treatment of overt hepatic encephalopathy; and AXA1125 for treating non-alcoholic steatohepatitis. It also develops AXA4010, a hematology product candidate; and AXA2678, a muscle product candidate. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was incorporated in 2008 and is based in Cambridge, Massachusetts.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-06-17 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

+4.63 (+2.34%)

USD79.44B 132.60 106.34
REGN Regeneron Pharmaceuticals, Inc

+12.43 (+2.37%)

USD55.78B 14.90 11.77
BNTX BioNTech SE

+10.35 (+5.08%)

USD49.23B -99,999.99 35.63
VRTX Vertex Pharmaceuticals Incorpo..

+0.87 (+0.46%)

USD48.53B 17.87 12.86
ALXN Alexion Pharmaceuticals, Inc

-0.58 (-0.32%)

USD39.90B 58.60 42.42
BGNE BeiGene, Ltd

-4.17 (-1.25%)

USD31.22B N/A N/A
GMAB Genmab A/S

-1.04 (-2.33%)

USD29.17B 26.59 3.71
SGEN Seagen Inc

+2.06 (+1.36%)

USD27.46B 42.22 39.29
RPRX Royalty Pharma plc

+0.52 (+1.19%)

USD26.73B 22.60 15.75
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing AXLA

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -18.30% 28% F 14% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -18.30% 28% F 14% F
Trailing 12 Months  
Capital Gain -26.26% 28% F 9% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -26.26% 28% F 9% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -1.04% 31% F 24% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -1.04% 30% F 20% F
Risk Return Profile  
Volatility (Standard Deviation) 31.54% 86% B 56% F
Risk Adjusted Return -3.29% 29% F 21% F
Market Capitalization 0.16B 28% F 28% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 3.03 62% D- 49% F
Price / Cash Flow Ratio -3.30 23% F 63% D
EV/EBITDA 0.07 84% B 97% A+
Management Effectiveness  
Return on Equity -104.56% 24% F 10% F
Return on Invested Capital -57.97% 43% F 14% F
Return on Assets -39.14% 21% F 7% F
Debt to Equity Ratio 33.46% 32% F 50% F
Technical Ratios  
Short Ratio 6.28 42% F 24% F
Short Percent 3.25% 77% C+ 52% F
Beta 1.38 48% F 34% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector